Merck has introduced its ADC Express services for the rapid production of ADCs, designed to reduce the time needed to produce development-grade constructs for target molecule identification.
Merck’s established platform technology can efficiently turn an antibody, linker and payload into an ADC. The company offers a platform approach to ADC constructs and bioconjugation, which is said to result in increased flexibility and speed.
The company’s ADC Express services include mini-prep scale (10–20 mg ADC construct ± column purification); medium-prep scale (~100 mg ADC ± column purification); and a certificate of testing with key quality attributes, including ADC concentration, payload density/DAR (drug antibody ratio) and monomer/aggregate content and free residual payload.
For companies that have a rich pipeline of monoclonal antibodies (mAbs) and want to enter the ADC space, Merck’s services allow them to obtain ADCs without having to invest in potent handling capabilities. Companies can either bring their own linker technology or procure a linker payload from Merck.
Traditionally, several CDMOs across the globe were involved in the development and production of ADC programs. Merck’s comprehensive ADC service portfolio combines the crucial steps of drug development and production — mAb solutions, linker, payload and the final conjugation — all from a single source.
Phone: 1800 800 097
Amsbio BioPORTER Protein Delivery Reagent
The BioPORTER Protein Delivery Reagent from Amsbio is a specialised, lipid-based reagent designed...
Amsbio StemFit Basic04CT stem cell medium
StemFit Basic04CT from Amsbio is an animal-origin-free, defined, ready-to-use medium designed to...
Takara Bio Europe Cellartis MSC EV Wonder GMP-grade medium
Takara Bio Europe has introduced a Good Manufacturing Practice (GMP)-grade version of Cellartis...
